PSMA-STEAP1 Dual Variable Domain Immunoglobulin DVD-Ig Molecules and Drug Conjugates

AbbVie Inc. has obtained publication of a patent application covering DVD-Ig molecules that simultaneously bind human PSMA (prostate-specific membrane antigen) and human STEAP1 (six-transmembrane epithelial antigen of prostate 1), along with drug conjugates incorporating these constructs. The application claims priority to a November 25, 2024 filing date and has been assigned Application No. 18958236. The technology falls under CPC classifications A61K and C07K (immunoglobulins, therapeutic conjugates).

This publication does not represent an issued patent or create immediate compliance obligations. Third parties developing PSMA/STEAP1-targeted therapies should consider this application when assessing freedom-to-operate and potential blocking positions. No regulatory action is required at this time; competitors may continue development but should monitor for subsequent prosecution history and potential issued claims.